Concurrent use of mifepristone and misoprostol for early medical abortion.
OBJECTIVE
This study was designed to evaluate the efficacy of using mifepristone and misoprostol concurrently for early medical abortion.


METHODS
A total of 90 women with undesired pregnancies <or= 49 days' gestation were enrolled. All women concurrently received oral mifepristone 200 mg and vaginal misoprostol 800 microg. Follow-up evaluation with transvaginal ultrasonography was performed 4 days and 2 weeks after treatment.


RESULTS
The complete abortion rate was 97.8% (88/90 women). The mean induction to abortion interval was 5.5 hours. The mean bleeding duration was 11.8 days. Patients found the side effects acceptable and reported a 91.1% (82 patients) satisfaction rate.


CONCLUSIONS
Concurrent administration of oral mifepristone and vaginal misoprostol is an efficacious regimen for medical abortion of pregnancies <or= 49 days of gestation.
Li
Yiu-Tai
YT
Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan.
Chen
Fu-Min
FM
Chen
Tien-Hui
TH
Li
Shu-Ching
SC
Chen
Min-Lung
ML
Kuo
Tsung-Cheng
TC
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods*; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011261:Pregnancy Trimester, First
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone